卡培他滨联合放射治疗老年中晚期食管癌的效果(1)
[摘要]目的 探讨卡培他滨联合放射治疗老年中晚期食管癌的效果。方法 选取2013年3月～2015年7月我院收治的76例老年中晚期食管癌患者作为研究对象，按照随机数字表法分为参照组(38例)与观察组(38例)。参照组患者给予放射治疗，观察组患者给予卡培他滨联合放射治疗，两组的疗程均为6周。比较两组患者的临床治疗效果、不良反应发生情况及治疗后3年内的生存情况。结果 观察组患者的总有效率(73.68%)高于参照组(50.00%)，差异有统计学意义(P<0.05)；观察组患者的1年生存率(84.21%)高于参照组(60.53%)，差异有统计学意义(P<0.05)；两组患者的不良反应总发生率比较，差异无统计学意义(P>0.05)。结论 卡培他滨联合放射治疗老年中晚期食管癌的效果显著，可有效缓解患者的病情，提高患者的生存率，且该治疗方式的安全性较高，轻微不良反应不影响患者病情的缓解，值得在临床治疗上广泛应用。
[关键词]卡培他滨；放射治疗；老年患者；中晚期食管癌；临床疗效
[中图分类号] R735.1 [文献标识码] A [文章编号] 1674-4721(2019)4(b)-0070-04
[Abstract] Objective To investigate the effect of Capecitabine combined with radiotherapy in the treatment of elderly patients with advanced esophageal cancer. Methods A total of 76 elderly patients with advanced esophageal cancer admitted to our hospital from March 2013 to July 2015 were selected as the study subjects， they were divided into control group (38 cases) and observation group (38 cases) according to random number table method. The control group was treated with radiotherapy， while the observation group was treated with Capecitabine combined with radiotherapy， the course of treatment in both groups was 6 weeks. The clinical efficacy， adverse reactions and survival within 3 years after treatment were compared between the two groups. Results The total effective rate of the observation group (73.68%) was higher than that of the control group (50.00%)， the difference was statistically significant (P<0.05). The 1-year survival rate of the patients in the observation group (84.21%) was higher than that in the control group (60.53%)， the difference was statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Capecitabine combined with radiotherapy in the treatment of elderly patients with advanced esophageal cancer has a remarkable effect. It can effectively alleviate the patient′s condition and improve the survival rate of patients. Moreover， the treatment method has a high safety， and minor adverse reactions do not affect the remission of patients'condition. It is worthy of wide application in clinical treatment.
[Key words] Capecitabine； Radiotherapy； Elderly patients； Advanced esophageal cancer； Clinical efficacy
食管癌是一種国内外都十分常见的恶性消化道肿瘤，在我国有着较高的发病率，且发病的概率会随年龄的增长而逐渐增加。有相关资料显示，我国的食管癌患者约占全世界的50%，其中大部分为老年男性群体[1]。该疾病的早期症状隐匿，往往难以被患者察觉，若出现发热、声音嘶哑、进行性吞咽困难等症状，则说明病情已经进入中晚期，肿瘤已经局部浸润器官或淋巴结，已经大面积向远处转移，不再适宜手术治疗，具有较高的危险性和死亡率[2-3]。放疗与化疗是中晚期食管癌的主要治疗手段，可通过杀灭癌细胞控制病情的进展，延长患者的生存时间。研究显示，与采用单一治疗方式相比，采用放疗与化疗联合治疗的疗效更佳，可延长患者的生存时间，降低死亡率[4]。本研究对老年中晚期食管癌患者采用卡培他滨联合放射治疗的治疗方式，探究其治疗效果，现报道如下。, 百拇医药(李济元 孙钦文 洪凤娟)
[关键词]卡培他滨；放射治疗；老年患者；中晚期食管癌；临床疗效
[中图分类号] R735.1 [文献标识码] A [文章编号] 1674-4721(2019)4(b)-0070-04
[Abstract] Objective To investigate the effect of Capecitabine combined with radiotherapy in the treatment of elderly patients with advanced esophageal cancer. Methods A total of 76 elderly patients with advanced esophageal cancer admitted to our hospital from March 2013 to July 2015 were selected as the study subjects， they were divided into control group (38 cases) and observation group (38 cases) according to random number table method. The control group was treated with radiotherapy， while the observation group was treated with Capecitabine combined with radiotherapy， the course of treatment in both groups was 6 weeks. The clinical efficacy， adverse reactions and survival within 3 years after treatment were compared between the two groups. Results The total effective rate of the observation group (73.68%) was higher than that of the control group (50.00%)， the difference was statistically significant (P<0.05). The 1-year survival rate of the patients in the observation group (84.21%) was higher than that in the control group (60.53%)， the difference was statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Capecitabine combined with radiotherapy in the treatment of elderly patients with advanced esophageal cancer has a remarkable effect. It can effectively alleviate the patient′s condition and improve the survival rate of patients. Moreover， the treatment method has a high safety， and minor adverse reactions do not affect the remission of patients'condition. It is worthy of wide application in clinical treatment.
[Key words] Capecitabine； Radiotherapy； Elderly patients； Advanced esophageal cancer； Clinical efficacy
食管癌是一種国内外都十分常见的恶性消化道肿瘤，在我国有着较高的发病率，且发病的概率会随年龄的增长而逐渐增加。有相关资料显示，我国的食管癌患者约占全世界的50%，其中大部分为老年男性群体[1]。该疾病的早期症状隐匿，往往难以被患者察觉，若出现发热、声音嘶哑、进行性吞咽困难等症状，则说明病情已经进入中晚期，肿瘤已经局部浸润器官或淋巴结，已经大面积向远处转移，不再适宜手术治疗，具有较高的危险性和死亡率[2-3]。放疗与化疗是中晚期食管癌的主要治疗手段，可通过杀灭癌细胞控制病情的进展，延长患者的生存时间。研究显示，与采用单一治疗方式相比，采用放疗与化疗联合治疗的疗效更佳，可延长患者的生存时间，降低死亡率[4]。本研究对老年中晚期食管癌患者采用卡培他滨联合放射治疗的治疗方式，探究其治疗效果，现报道如下。, 百拇医药(李济元 孙钦文 洪凤娟)